Cerora

Executive Summary

Cerora is a US-based neurodiagnostics company developing the Borealis platform, a portable biosensor system designed to objectively assess brain health, with an initial focus on concussion and mild traumatic brain injury (mTBI). Founded in 2013 and headquartered in Bethlehem, Pennsylvania, the company aims to address the significant unmet need for rapid, objective, and accessible diagnostic tools in concussion management. The Borealis platform integrates electroencephalography (EEG) and other biosensors to provide clinicians with real-time, quantitative data, potentially improving diagnostic accuracy and enabling more informed clinical decisions. Concussion diagnosis currently relies heavily on subjective symptom reports and cognitive testing, leaving room for objective biomarkers to enhance care, especially in sports, military, and emergency settings. Despite being in a promising niche, Cerora operates in a competitive landscape with other neurodiagnostic startups. The company has not publicly disclosed funding rounds or revenue, suggesting it is still in earlier stages of development or commercialization. Key milestones ahead include regulatory clearance, clinical validation, and strategic partnerships. If successful, Cerora could become a standard tool for concussion assessment, reducing the risk of mismanagement and long-term neurological damage. However, execution risk is significant given the need for regulatory approval, market adoption, and reimbursement. The company's private status and lack of recent news updates make near-term visibility low, but the clinical need and technological approach support a moderate conviction.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Borealis Platform40% success
• H2 2026Publication of Clinical Validation Study in Peer-Reviewed Journal60% success
• H1 2027Strategic Partnership with Major Sports League or Military Branch30% success